Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Karatas OF, Wang J, Shao L, Ozen M, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2017 Jul 24;8(36):60243-60256. doi: 10.18632/oncotarget.19521. eCollection 2017 Sep 1.

2.

Expression of prostate stem cell antigen is downregulated during flavonoid-induced cytotoxicity in prostate cancer cells.

Zhang Q, Cheng G, Qiu H, Wang Y, Wang J, Xu H, Zhang T, Liu L, Tao Y, Ren Z.

Exp Ther Med. 2017 Aug;14(2):1795-1801. doi: 10.3892/etm.2017.4638. Epub 2017 Jun 21.

3.

When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.

Lin Y, Mao Q, Chen B, Wang L, Liu B, Zheng X, Xie L.

BMC Urol. 2017 Jun 12;17(1):41. doi: 10.1186/s12894-017-0229-z.

4.

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre.

Noronha V, Joshi A, Muddu VK, Maruti Patil V, Prabhash K.

Case Rep Oncol. 2016 Aug 30;9(2):506-515. eCollection 2016 May-Aug.

5.

Predictive factors for biochemical recurrence in radical prostatectomy patients.

Turk H, Celik O, Un S, Yoldas M, İsoglu CS, Karabicak M, Ergani B, Koc G, Zorlu F, Ilbey YO.

Cent European J Urol. 2015;68(4):404-9. doi: 10.5173/ceju.2015.606. Epub 2015 Nov 30.

6.

The role of an abnormal prostate-specific antigen level and an abnormal digital rectal examination in the diagnosis of prostate cancer: A cross-sectional study in Qatar.

Al Rumaihi K, Al Jalham K, Younes N, Majzoub AA, Shokeir AA.

Arab J Urol. 2013 Dec;11(4):355-60. doi: 10.1016/j.aju.2013.08.014. Epub 2013 Oct 20.

7.

A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.

Basu S, Majumder S, Bhowal A, Ghosh A, Naskar S, Nandy S, Mukherjee S, Sinha RK, Basu K, Karmakar D, Banerjee S, Sengupta S.

PLoS One. 2015 May 4;10(5):e0125560. doi: 10.1371/journal.pone.0125560. eCollection 2015.

8.

The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria.

Agalliu I, Adebiyi AO, Lounsbury DW, Popoola O, Jinadu K, Amodu O, Paul S, Adedimeji A, Asuzu C, Asuzu M, Ogunbiyi OJ, Rohan T, Shittu OB.

BMC Public Health. 2015 Apr 26;15:425. doi: 10.1186/s12889-015-1754-x.

9.

An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP.

World J Urol. 2015 Nov;33(11):1677-87. doi: 10.1007/s00345-015-1514-7. Epub 2015 Feb 20.

10.

Serum prostate-specific antigen levels and type of work in tire manufacturing workers.

Kim SH, Jang KH, Park WJ, Kwon DH, Kang WY, Lim HM, Moon JD.

Ann Occup Environ Med. 2014 Nov 4;26(1):50. doi: 10.1186/s40557-014-0050-z. eCollection 2014.

11.

Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk.

Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, Liang Z, Hu ZH, Li SQ, Zheng XY, Xie LP.

World J Surg Oncol. 2014 Oct 5;12:304. doi: 10.1186/1477-7819-12-304.

12.

Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population.

Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T, Deliveliotis C.

Asian J Androl. 2015 Jan-Feb;17(1):98-105. doi: 10.4103/1008-682X.136445.

13.

High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness.

Tamada T, Kanomata N, Sone T, Jo Y, Miyaji Y, Higashi H, Yamamoto A, Ito K.

PLoS One. 2014 May 6;9(5):e96619. doi: 10.1371/journal.pone.0096619. eCollection 2014.

14.

Reliability of maximal cardiopulmonary exercise testing in men with prostate cancer.

Scott JM, Hornsby WE, Lane A, Kenjale AA, Eves ND, Jones LW.

Med Sci Sports Exerc. 2015 Jan;47(1):27-32. doi: 10.1249/MSS.0000000000000370.

15.

Geographic variations and temporal trends in prostate cancer in Martinique over a 25-year period.

Dieye M, Banydeen R, Macni J, Michel S, Veronique-Baudin J, Sasco A, Escarmant P, Joachim C.

BMC Res Notes. 2014 Apr 23;7:262. doi: 10.1186/1756-0500-7-262.

16.

Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population.

Qian J, Zhou H, Chen J, Ding Q, Cao Q, Qin C, Shao P, Li P, Cai H, Meng X, Ju X, Wang M, Zhang Z, Li J, Hua L, Yin C.

PLoS One. 2014 Feb 21;9(2):e85609. doi: 10.1371/journal.pone.0085609. eCollection 2014.

17.

Potential of magnetic nanoparticles for targeted drug delivery.

Yang HW, Hua MY, Liu HL, Huang CY, Wei KC.

Nanotechnol Sci Appl. 2012 Aug 27;5:73-86. doi: 10.2147/NSA.S35506. Review.

18.

Contrast-enhanced US of the prostate with time/intensity curves: Preliminary results.

Valentino M, De Matteis M, Casadio Baleni M, Monteduro F, Paganelli F, Pavlica P, Barozzi L.

J Ultrasound. 2008 Mar;11(1):8-11. doi: 10.1016/j.jus.2007.10.004. Epub 2008 Feb 20.

19.

An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.

Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, Dai B, Ye DW.

Asian J Androl. 2013 Mar;15(2):231-5. doi: 10.1038/aja.2012.116. Epub 2013 Feb 4.

20.

Optimizing the management of high-risk, localized prostate cancer.

Sundi D, Jeong BC, Lee SB, Han M.

Korean J Urol. 2012 Dec;53(12):815-20. doi: 10.4111/kju.2012.53.12.815. Epub 2012 Dec 20.

Supplemental Content

Support Center